F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas

Leukemia and Lymphoma

Volumn 48, Issue 8, 2007, Pages 1531-1538

  Bishu, S ^a   Quigley, J M ^b   Schmitz, J ^c   Bishu, S R ^d   Stemm, R A ^b   Olsasky, S M ^b   Paknikar, S ^b   Holdeman, K H ^c   Armitage, J O ^b   Hankins, J H ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diagnostic accuracy; PET; PTCL

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCULATION; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA ANALYSIS; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MALE; PERIPHERAL T CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34547988328     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701344915     Document Type: Article

References (30)

1. (1997) The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89, pp. 3909-3918.
2. (2001) Mature T and NK cell neoplasms, IARC Press, Lyon
3. Armitage, J. O., Vose, J. M. and Weisenburger, D. D. (2004) Towards understanding the peripheral T-cell lymphomas. Ann Oncol, 15, pp. 1447-1449.
4. Evens, A. M. and Gartenhaus, R. B. (2004) Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol, 5, pp. 289-303.
5. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K. and Buck, A. (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 25, pp. 571-578.
6. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J. A. and Zhuang, H. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, pp. 3875-3876.
7. Israel, O., Keidar, Z. and Bar-Shalom, R. (2004) Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med, 34, pp. 166-179.
8. Willemze, R., Jaffe, E. S., Burg, G., Cerroni, L., Berti, E. and Swerdlow, S. H. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, pp. 3768-3785.
9. Armitage, J. O. (2005) Staging non-Hodgkin lymphoma. CA Cancer J Clin, 55, pp. 368-376.
10. Lamberg, S. I. and Bunn Jr, P. A. (1979) Cutaneous T-cell lymphomas. Summary of the Mycosis Fungoides Cooperative Group-National Cancer Institute Workshop. Arch Dermatol, 115, pp. 1103-1105.
11. Delbeke, D CR, Guiberteau, M. J., Brown, M. L., Royal, H. D., Seigel, B. A. and Townsend, D. W. (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0, Society of Nuclear Medicine Procedure Guidelines
12. Miller, E., Metser, U., Avrahami, G., Dvir, R., Valdman, D. and Sira, L. B. (2006) Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr, 30, pp. 689-694.
13. Buchmann, I., Reinhardt, M., Elsner, K., Bunjes, D., Altehoefer, C. and Finke, J. (2001) 2-(Fluorine-18)fluoro-2-deoxy--glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer, 91, pp. 889-899.
14. Tatsumi, M., Cohade, C., Nakamoto, Y., Fishman, E. K. and Wahl, R. L. (2005) Direct comparison of FDG PET and CT findings in patients with lymphoma: Initial experience. Radiology, 237, pp. 1038-1045.
15. Kostakoglu, L., Leonard, J. P., Kuji, I., Coleman, M., Vallabhajosula, S. and Goldsmith, S. J. (2002) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer, 94, pp. 879-888.
16. Rizvi, M. A., Evens, A. M., Tallman, M. S., Nelson, B. P. and Rosen, S. T. (2006) T-cell non-Hodgkin lymphoma. Blood, 107, pp. 1255-1264.
17. Kumar, R., Xiu, Y., Zhuang, H. M. and Alavi, A. (2006) 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol, 155, pp. 357-363.
18. Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D. and Dick, S. (2006) Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol, 142, pp. 577-584.
19. Valencak, J., Becherer, A., Der-Petrossian, M., Trautinger, F., Raderer, M. and Hoffmann, M. (2004) Positron emission tomography with [18F] 2-fluoro--2-deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica, 89, pp. 115-116.
20. Howlett, D. C., Wong, W. L., Smith, N. P. and Ayers, A. B. (1995) Computed tomography in the evaluation of cutaneous T-cell lymphoma. Eur J Radiol, 20, pp. 39-42.
21. Bass, J. C., Korobkin, M. T., Cooper, K. D., Kane, N. M. and Platt, J. F. (1993) Cutaneous T-cell lymphoma: CT in evaluation and staging. Radiology, 186, pp. 273-278.
22. Miketic, L. M., Chambers, T. P. and Lembersky, B. C. (1993) Cutaneous T-cell lymphoma: Value of CT in staging and determining prognosis. AJR Am J Roentgenol, 160, pp. 1129-1132.
23. Kulin, P. A., Marglin, S. I., Shuman, W. P., Chew, D. E. and Olerud, J. E. (1990) Diagnostic imaging in the initial staging of mycosis fungoides and Sezary syndrome. Arch Dermatol, 126, pp. 914-918.
24. Wohrer, S., Chott, A., Drach, J., Puspok, A., Hejna, M. and Hoffmann, M. (2004) Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol, 15, pp. 1680-1683.
25. Hoffmann, M., Vogelsang, H., Kletter, K., Zettinig, G., Chott, A. and Raderer, M. (2003) 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut, 52, pp. 347-351.
26. Hadithi, M., Mallant, M., Oudejans, J., van Waesberghe, J. H., Mulder, C. J. and Comans, E. F. (2006) 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med, 47, pp. 1622-1627.
27. Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J. and Vandenberghe, P. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol, 19, pp. 414-419.
28. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J. and de Groot, T. (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol, 13, pp. 1356-1363.
29. Shapiro, M., Yun, M., Junkins-Hopkins, J. M., Vittorio, C. C., Schulman, N. and Saidman, B. H. (2002) Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Am Acad Dermatol, 47, pp. 623-628.
30. Meignan, M., Haioun, C., Itti, E., Rahmouni, A. and Reyes, F. (2006) Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma, 6, pp. 306-313.